submit to the journals

AAN Highlights

flipper_slider

Editor's Choice

Daniel Kremens (Sidney Kimmel Medical College, Thomas Jefferson University) discusses his recently published article co-authored with Stuart Isaacson, entitled: Treatment Advances in Parkinson’s Disease...

AAN Highlights Videos

Edwin George (Wayne State University, MI) discusses the limitations of current therapeutic options for multiple system atrophy (MSA), and what have been the most promising recent advances toward management of the condition. Questions 1. What are the limitations of current therapeutic options in...
Edwin George (Wayne State University, MI) explains why the diagnosis of multiple system atrophy (MSA) is so challenging and what is known in terms of causes of the condition. Questions 1. Why is the diagnosis of multiple system atrophy (MSA) so challenging? (0:11) 2. Are there any known causes...
Edwin George (Wayne State University, MI) describes the often overlooked condition, multiple system atrophy (MSA), and the important mission of Defeat MSA (https://defeatmsa.org/). Speaker disclosure: Edwin George is a pro bono advisor on Defeat MSA's scientific and medical board. He also...
Rajesh Pahwa (University of Kansas Medical Center) discusses the management of dyskinesia in Parkinson's disease with a focus on amantadine (GOCOVRI™), the first and only FDA-approved medication for this indication. Questions 1. What is the mechanism of action of amantadine in dyskinesia? (0:11...
Rajesh Pahwa (University of Kansas Medical Center) discusses essential tremor and exciting findings presented in his emerging science poster presentation entitled: Non-Invasive Peripheral Nerve Stimulation for Symptomatic Relief of Hand Tremor in Essential Tremor (abstract available here)....
David Hafler (Yale School of Medicine, CT) considers recent developments in understanding of genetic risk, as well as the roles of regulatory T cells and B cells in multiple sclerosis (MS), and shares his view on what he considers to be the most important therapeutic targets in MS and remaining...
Thapanee Somboon (Cleveland Clinic, OH) talks us through the key findings of her two presentations, which focused on the prevalence of high risk obstructive sleep apnea and insomnia in neurological populations (abstract available here) and the performance of sleep apnea screening tools in former...
Cris Constantinescu (University of Nottingham, Queen's Medical Centre, UK), our Editor-in Chief of European Neurological Review, discusses the background and findings of his presentation comparing the immunomodulatory activity of mesenchymal stem cells from patients with secondary progressive...
Cris Constantinescu (University of Nottingham, Queen's Medical Centre, UK), our Editor-in Chief of European Neurological Review, discusses the challenges and recommendations for diagnosing neuro-Behçet’s, as well as methods for managing the condition. Questions 1. What are the major challenges...
Mark Freedman (Ottawa Hospital and Ottawa Hospital Research Institute), a recent welcome addition to our editorial board for US Neurology, considers treatment biomarkers in multiple sclerosis including discussion around his presentation on neurofilament light chain (NF-L) levels before and after...
Werner Poewe (Medical University Innsbruck, Austria), a recent welcome addition to our editorial board for European Neurological Review, shares his insights and highlights on Parkinson's disease from the American Academy of Neurology (AAN) Annual Meeting 2018. Questions 1. What have been the...
John Bodensteiner (Consultant, Child and Adolescent Neurology), our Paediatric Neurology Section Editor for US Neurology, shares his expert perspective on Duchenne muscular dystrophy. Questions 1. What do you consider the most promising current and emerging treatment options for Duchenne...
John Bodensteiner (Consultant, Child and Adolescent Neurology), our Paediatric Neurology Section Editor for US Neurology, discusses the impact recent advances in molecular and genetic diagnosis have had in paediatric neurology on conditions such as Duchenne muscular dystrophy and spinal muscular...
Richard Finkel (Nemours Children's Hospital), recipient of this year's Sidney Carter Award in Child Neurology, speaks to us on the topic of his presentation during the AAN 2018 Presidential Plenary Session, entitled: Spinal Muscular Atrophy Is a Treatable Neurodegenerative Disease. Questions 1...
Said Beydoun (Keck Medical Center, University of Southern California), our Editor-in Chief of US Neurology, discusses his recently published article co-authored with Jeffrey Rosenfeld, entitled: Edaravone in Amyotrophic Lateral Sclerosis—Lessons from the Clinical Development Program and the...